32 min listen
Season 7, Episode 1: Unraveling the Link Between Dupilumab and Cutaneous T-Cell Lymphoma
Season 7, Episode 1: Unraveling the Link Between Dupilumab and Cutaneous T-Cell Lymphoma
ratings:
Length:
20 minutes
Released:
Apr 22, 2024
Format:
Podcast episode
Description
Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed?
Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.
While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it.
As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL. Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.
Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.
While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it.
As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL. Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.
Released:
Apr 22, 2024
Format:
Podcast episode
Titles in the series (62)
Season 1 Episode 1 (Androgenetic Alopecia and Alopecia Areata): REFERENCED STUDIES FOR ANDROGENETIC ALOPECIA Silva et al (starts at 1:10). Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair Loss: 0.25 mg versus 1 mg. Journal of the American Academy of Dermatology; Online Ja... by Evidence Based Hair